JB Chemicals & Pharmaceuticals is currently trading at Rs. 307.00, down by 13.10 points or 4.09% from its previous closing of Rs. 320.10 on the BSE.
The scrip opened at Rs. 309.45 and has touched a high and low of Rs. 309.45 and Rs. 298.20 respectively. So far 12,000 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 363.05 on 17-May-2017 and a 52 week low of Rs. 255.00 on 28-Sep-2017.
Last one week high and low of the scrip stood at Rs. 324.95 and Rs. 298.20 respectively. The current market cap of the company is Rs. 2,565.60 crore.
The promoters holding in the company stood at 55.84%, while Institutions and Non-Institutions held 18.07% and 26.10% respectively.
JB Chemicals & Pharmaceuticals (JBCPL) has received an order from Office of Member Secretary, Pollution Control Committee, Daman (PCC) directing the closure of the company’s formulation manufacturing facility at Daman on the ground of alleged deviation of standards of treated waste water released from ETP outlet of the said facility. During 2017-18, the total sales of formulations manufactured at the said facility amounted to about Rs 223 crore.
The company does not accept the analytical results obtained by the said authority. The company is taking all necessary steps so as to resume operations at the said facility in line with the standards prescribed by the said authority. The company’s said facility has received all NOC/Consents to operate under applicable environmental laws and is operating well within the framework of law.
JB Chemicals & Pharmaceuticals is engaged in manufacturing of pharmaceutical specialties in various dosage forms, herbal remedies, diagnostics, generic drugs, active pharmaceutical ingredients (APIs).
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1679.85 |
| Dr. Reddys Lab | 1333.05 |
| Cipla | 1305.85 |
| Zydus Lifesciences | 947.10 |
| Lupin | 2340.20 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: